Last reviewed · How we verify
Memantine Tab. 10mg
At a glance
| Generic name | Memantine Tab. 10mg |
|---|---|
| Also known as | Ebixa Tab. 10mg |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge (PHASE2)
- Efficacy and Safety of memanTine in the Treatment Of Frequently symPtomatic Atrial Premature Beats (PHASE2)
- Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis (PHASE1)
- Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy (PHASE2)
- Pharmacokinetics of BPDO-1603 or BPDO-16031 and BPDO-16033 Administration in Healthy Adults (PHASE1)
- Memantine for Refractory OCD Patients (PHASE3)
- Evaluation of Memantine Versus Placebo on Ischemic Stroke Outcome (PHASE3)
- CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Memantine Tab. 10mg CI brief — competitive landscape report
- Memantine Tab. 10mg updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI